More than two million people worldwide are being treated for end-stage renal disease (ESRD), and treatment models and access to treatment widely differ. Here’s what to know about ESRD treatment modalities around the world, patient survival rates and more.
Unadjusted five-year survival was 60% in Japan, 39% in the U.S., and 41% in Europe for patients starting dialysis, and unadjusted five-year survival was 52% in Malaysia and 44% in Taiwan.
Unadjusted five-year survival was 52% in Malaysia and 44% in Taiwan.
Survival rates for ESRD are higher in Europe than the U.S. This could be explained by the inferiority of national standards of care, a higher prevalence of patients with diabetes and differences in practice patterns.
Survival rates in Japan and other east Asian countries substantially exceeds other countries. This could be because of lower background mortality and fewer transplant recipients in these countries.
The Advancing American Kidney Health Act Could Impact Your Patients, Clinic and Kidney Care Staff